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Abstract
Purpose—Tumor-infiltrating lymphocytes (TILs) have prognostic significance in many cancers,
yet their roles in glioblastoma (GBM) have not been fully defined. We hypothesized TILs in GBM
are associated with molecular alterations, histologies and survival.
Experimental Design—We used data from The Cancer Genome Atlas (TCGA) to investigate
molecular, histologic and clinical correlates of TILs in GBMs. Lymphocytes were categorized as
absent, present or abundant in histopathologic images from 171 TCGA GBMs. Associations were
examined between lymphocytes and histologic features, mutations, copy number alterations, CpG
island methylator phenotype, transcriptional class and survival. We validated histologic findings
using CD3G gene expression.
Results—We found a positive correlation between TILs and GBMs with gemistocytes,
sarcomatous cells, epithelioid cells and giant cells. Lymphocytes were enriched in the
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mesenchymal transcriptional class and strongly associated with mutations in NF1 and RB1. These
mutations are frequent in the mesenchymal class and characteristic of gemistocytic, sarcomatous,
epithelioid and giant cell histologies. Conversely, TILs were rare in GBMs with small cells and
oligodendroglioma components. Lymphocytes were depleted in the classical transcriptional class
and in EGFR-amplified and homozygous PTEN-deleted GBMs. These alterations are
characteristic of GBMs with small cells and GBMs of the classical transcriptional class. No
association with survival was demonstrated.
Conclusions—TILs were enriched in GBMs of the mesenchymal class, strongly associated with
mutations in NF1 and RB1 and typical of histologies characterized by these mutations.
Conversely, TILs were depleted in the classical class, EGFR-amplified and homozygous PTEN-
deleted tumors and rare in histologies characterized by these alterations.
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INTRODUCTION
Glioblastoma (GBM) is the most common and highest grade astrocytoma (World Heath
Organization, grade IV). Despite advances in diagnosis and treatment, GBM remains
incurable with an average survival of 15 months.(1) Although characterized by dramatic
molecular and histologic heterogeneity, current adjuvant treatments inhibit cell division
nonspecifically and are not tailored to specific subsets.(1, 2) Molecular classifications of
GBM have revealed distinct subclasses with clinical relevance, opening the way for
therapies to be directed at class-specific mechanisms.(3, 4) Immunotherapy, for example,
has great potential as a tailored therapy. Already FDA-approved for prostate cancer and
metastatic melanoma and in clinical trials for other cancer types, immunotherapy remains
promising for patients with GBM, offering high tumor-specificity and long-term tumor
surveillance.(5–7)
Tumor-infiltrating lymphocytes (TILs) are present in subsets of GBM, yet their biologic
activities and clinical relevance have not been fully explored. The presence of TILs suggests
an anti-tumor adaptive immune response and might be expected to impact survival.
Lymphocytes are present within the stroma of other cancers, including melanoma, colorectal
and ovarian carcinoma, where their presence is associated with improved patient outcomes.
(8–17) A recent study suggested TILs have prognostic significance in GBM, yet others have
shown lymphocytes may impart a less favorable prognosis.(18–21)
A complex relationship exists between the development of cancer, the immunologic
response to it and the immunosuppression it causes. In GBM, tumor-mediated
immunosuppression is thought to explain functional deficits in cytotoxic lymphocytes.(22)
Regulatory lymphocytes are elevated in patients with GBM and suppress anti-tumor activity
by inhibiting secretion of cytotoxic cytokines from effector lymphocytes.(23, 24) Thus,
while lymphocytes and other immune cells infiltrate GBM, an immunosuppressive tumor
milieu likely prevents successful immune-mediated tumor eradication. Recent clinical trials
have focused on augmenting the anti-tumor immune response with tumor vaccines or
reversing tumor-mediated immunosuppression.
Molecular alterations in GBM and other cancers may be immunogenic. For example,
microsatellite instability and methylation aberrations are independent predictors of
lymphocyte density in colorectal cancer.(14) Given its molecular and histologic
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heterogeneity, subsets of GBM may be more immunogenic and responsive to
immunotherapy, yet little is known about the relation between immune cells and the tumor
microenvironment or molecular classes in GBM. Therefore, the purpose of this study was to
identify molecular and histologic correlates of the immune response in GBM. We used
whole-slide digitized images of GBMs from The Cancer Genome Atlas (TCGA) linked to
multiplatform molecular data. These may provide insight into the biologic significance of
TILs in GBM and impact therapy.
MATERIALS AND METHODS
We performed an integrated molecular and histologic analysis using data from TCGA,
which molecularly characterized GBMs across multiple platforms, including single-
nucleotide polymorphism (SNP) genotyping, mRNA and microRNA profiling, DNA
sequencing and methylation analysis.(2) Clinical data, including treatment and survival, is
also available.
Digitized Images used for Morphological Analysis
Permanent section histologic slides from TCGA GBMs were provided by contributing
institutions. Slides were scanned and digitized at 20X resolution by a high-throughput digital
scanner (Aperio, Inc.) at the TCGA Biospecimen Core Resource located at the International
Genomics Consortium (Intgen, Phoenix, AZ). The number of slides available for review
ranged from 1–9 per case (median, 3).
Ratings of TILs and other Histopathologic Features
TCGA consortium neuropathologists annotated digitized permanent section histologic slides
from 122 TCGA cases for 18 histopathologic features, including inflammation,
angiogenesis, necrosis, lymphocytes, common morphologic subtypes and others (Table 1).
“Inflammation” as a general category was defined by the presence of inflammatory cells,
including lymphocytes, macrophage, neutrophils or their combination. Lymphocytes were
identified as small round cells with scant cytoplasm and darkly staining nuclei.
Lymphocytes and all other histopathologic features were categorized as absent (0), present
(1+) or abundant (2+) by two neuropathologists (MC, KA, RM, NL, RM, MJS, DJB) and
adjudicated by a third. Cases with a complete absence of lymphocytes were labeled 0
(absent). Cases with lymphocytes in <50% of tumor tissue were categorized 1+ (present),
while cases with lymphocytes in ≥50% were categorized 2+ (abundant) (Figure 1). In
addition to these 122 cases, an additional 49 TCGA cases from Emory University Hospital
and Henry Ford Health System were annotated for the same 18 histopathologic features
using the same criteria by two TCGA neuropathologists (DJB, MJS). All digitized histologic
sections and TCGA neuropathology ratings were obtained from the TCGA portal (http://
tcga-data.nci.nih.gov.proxy.library.emory.edu/tcga/tcgaHome2.jsp; last accessed November
28, 2012). Digitized images and corresponding neuropathology ratings were the primary
source of data.
Mutations, Copy Number Alterations, Methylation Status and Transcriptional Class
We obtained TCGA mutation and copy number data from the Memorial Sloan Kettering
Cancer Genomics Portal (http://www.cbioportal.org/public-portal; last accessed November
28, 2012).(25) Mutation data from whole exome sequencing (NextGen) was obtained for 99
cases. Putative copy-number calls determined with GISTIC 2.0 were obtained for 153 cases.
CpG island methylator phenotype (G-CIMP) status was available for 124 cases.
Transcriptional class labels for the Verhaak classification were obtained for 162 cases from
the TCGA Advanced Working Group. The updated Verhaak labeling extends the original
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labeled set presented in Verhaak et al. by using the originally labeled samples along with
Affymetrix HT_HG-U133A data to label previously unclassified samples.(3)
Validation Dataset
CD3G is the gene that encodes the T-cell surface marker CD3. We used CD3G expression
data from TCGA as a marker of lymphocytes to validate our histologic findings in the same
set of tumors. CD3G expression data was obtained from the TCGA portal (http://tcga-
data.nci.nih.gov.proxy.library.emory.edu/tcga/tcgaHome2.jsp; last accessed February 1,
2012).
Statistical Analyses
Associations between lymphocytes and other histopathologic features were assessed using
the Mantel-Haenzel chi-square and exact test and Spearman correlation for ordinal
comparisons (0, 1+, 2+ vs 0, 1+, 2+). The Mantel-Haenzel exact test was used when the cell
count was <5 in 25% or more of cells. Chi-square and Fisher’s exact test were used for all
dichotomous comparisons (0 vs 1+, 2+ combined or 0, 1+ combined vs 2+). We combined
categories to identify associations driven by cases with either complete absence or
abundance of lymphocytes. The association of lymphocytes with mutations, copy number
alterations and G-CIMP status were also assessed using chi-square and Fisher’s exact test.
Fisher’s exact test was used when the cell count was <5 in 25% or more of cells.
Associations between lymphocytes and transcriptional class were examined using chi-square
and Fisher’s exact test. The Spearman correlation was used to measure the correlation
between lymphocytes and CD3G expression. Wilcoxon two-sample or Kruskal-Wallis tests
were used to detect differences in CD3G expression according to lymphocytes, mutation or
copy number status and transcriptional class.
Survival Analysis
Clinical data was obtained from the TCGA data portal. Survival was taken as “days to
death” for uncensored patients and “days to last follow-up” for right-censored patients. The
association between TILs and survival was examined using the log-rank test.
All p-values reported are two-sided and regarded as statistically significant if p<0.05. The
software used for statistical analysis was SAS Version 9.3 (SAS Institute Inc., Cary NC).
RESULTS
TILs are differentially distributed in GBM
Within the 171 GBMs reviewed for this study, tumor-infiltrating lymphocytes (TILs) were
absent (0) in 93 cases (54%), present (1+) in 59 cases (35%) and abundant (2+) in 19 cases
(11%). There was no significant association between the number of slides analyzed for each
case and the level of lymphocytes annotated.
TILs are associated with specific histopathologic features in GBM
GBMs show a tremendous degree of histologic variability and numerous morphologic
subtypes have been recognized, including fibrillary, gemistocytic, epitheliod, small cell,
giant cell, gliosarcoma and GBM with oligodendroglioma component. To determine if TILs
correlated with specific GBM morphologies or other histopathologic features, we examined
their associations using the Mantel-Haenzel chi-square test and Spearman correlation (Table
1). All variables, including lymphocytes and other histopathologic features were categorized
as 0, 1+ or 2+. We detected a strong positive correlation between TILs and specific tumor
cell morphologies that included gemistocytes, sarcomatous cells, epithelioid cells and giant
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cells (all p<0.05) (Figure 2). Conversely, TILs were depleted in GBMs characterized by
small cells and oligodendroglial cells (both p<0.05). Among other features analyzed, TILs
were most tightly correlated with the findings of inflammation (as a general category) and
macrophages (both p<0.05). TILs were also statistically associated with both forms of
necrosis annotated (pseudopalisading and zonal) (both p<0.05).
TILs are associated with specific mutations in GBM
In the initial TCGA analysis of GBM, eight genes were identified as significantly mutated,
including TP53, PTEN, NF1, EGFR, ERBB2, RB1, PIK3R1 and PIK3CA (genes attaining a
false discovery rate <0.1).(2) A subsequent, unbiased genomic analysis identified recurrent
mutations in isocitrate dehydrogenase 1 (IDH1).(26) We examined associations between
lymphocytes (0, 1+, 2+) and mutations (mutant vs wild type) for these genes using chi-
square and Fisher’s exact test (Table 2). Out data set contained no cases with ERBB2
mutations.
Among cases with mutational data, lymphocytes were absent (0) in 52, present (1+) in 38
and abundant (2+) in 9. We found lymphocytes were strongly associated with mutations in
neurofibromatosis 1 (NF1) and retinoblastoma 1 (RB1) (both p<0.05). Nine cases with
absent (0) lymphocytes were NF1-mutant (9/52, 17%), while 44% of cases with abundant
(2+) lymphocytes harbored mutations in NF1 (4/9). Two cases with absent (0) lymphocytes
harbored mutations in RB1 (2/52, 4%). Of cases with lymphocytes present (1+), six were
RB1 mutants (6/32, 16%). Two cases with abundant (2+) lymphocytes harbored mutations in
RB1 (2/9, 22%).
There was a trend towards significance for TP53 mutations (p=0.12), particularly when
cases with present (1+) and abundant (2+) lymphocytes were combined (p=0.06). 25% of
cases with absent (0) lymphocytes were TP53-mutant (13/52), while 43% of cases with
present (1+) or abundant (2+) lymphocytes harbored mutations in TP53 (20/47).
Since mutations in TP53 are characteristic of both the proneural and mesenchymal
transcriptional class, we investigated if mutations were overrepresented in one of these two
transcriptional classes.(3) 20 cases harbored mutations in TP53 and had present (1+) or
abundant (2+) lymphocytes. Nine (45%) belonged to the mesenchymal transcriptional class
and five (25%) belonged to the proneural class (p>0.05).
TILs are associated with specific copy number alterations in GBM
Significant copy number alterations (CNAs) were also identified in the initial TCGA global
analysis publication, including amplifications of EGFR, CDK4, PDGFRA, MDM2, MDM4,
MET, CDK6, MYCN, CCND2, PIK3CA and AKT3 and deletions of CDKN2A/B, PTEN,
CDKN2C, RB1, PARK2 and NF1.(2) We examined the association between TILs and these
recurrent amplifications and deletions using chi-square and Fisher’s exact test (Table 3).
Lymphocytes were depleted in EGFR-amplified tumors (p<0.05). Amplification of EGFR
was present in 65% of cases with absent (0) lymphocytes (53/82) compared to 48% of cases
with present (1+) or abundant (2+) lymphocytes. Only 35% of cases with abundant (2+)
lymphocytes were EGFR-amplified.
TILs were also depleted in tumors with homozygous deletions of PTEN (p<0.05). 78% of
cases with homozygous PTEN-deletion (14/18) had absent (0) lymphocytes. 17% of PTEN-
deleted cases had present (1+) lymphocytes (3/18), while only 5% of cases had abundant
(2+) lymphocytes (1/18). There was a trend towards significance for NF1 deletions
(p=0.07). No other associations between TILs and copy number alterations were noted.
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TILs are not associated with the CpG island methylator phenotype
G-CIMP positive tumors represent less than 10% of GBMs, but have significantly improved
survival compared to G-CIMP negative tumors.(27) IDH1 mutations have been shown to
establish the G-CIMP phenotype.(28) We examined the association between TILs and the
CpG island methylator phenotype using chi-square and Fisher’s exact test (data not shown).
TILs were not associated with G-CIMP status (p>0.05).
TILs are related to transcriptional class
Verhaak et al. identified four transcriptional classes of GBM using TCGA gene expression
data: proneural, neural, classical and mesenchymal.(3) To determine if there was an
association between transcriptional class and TILs, we examined each class for its
distribution of lymphocytes using chi-square and Fisher’s exact test (Table 4). We found
TILs were strongly associated with transcriptional class (p<0.05).
TILs were enriched in the mesenchymal class compared to all other classes combined
(p<0.05). 42% of cases (30/72) with a lymphocytic infiltrate (1+ or 2+) belonged to the
mesenchymal class. However, when classical tumors were excluded, there was no
statistically significant enrichment of TILs in the mesenchymal class compared to the
proneural and neural classes (p>0.05). Cases with abundant lymphocytes were heavily
enriched in mesenchymal transcriptional class. 71% of cases (12/17) with abundant
lymphocytes (2+) belonged to the mesenchymal class, whereas 12% were proneural, 12%
neural and 6% were classical, representing statistically significant enrichment (p<0.05).
When classical cases were excluded, there was a still a strong trend towards statistically
significant enrichment of abundant (2+) TILs in the mesenchymal class compared to the
proneural and neural classes (p=0.07).
Conversely, TILs were depleted in the classical transcriptional case compared to all other
classes combined (p<0.05). 74% of classical cases (31/42) were characterized by absent (0)
lymphocytes, representing statistically significant depletion (p<0.05). Only one case with
abundant (2+) lymphocytes belonged to the classical transcriptional class (1/17). When
mesenchymal tumors were excluded, there was still a trend towards statistically significant
depletion of TILs (1+ and 2+) in the classical class compared to the proneural and neural
classes (p=0.053).
CD3G gene expression is positively correlated with lymphocytes, mutations in TP53, RB1
and the mesenchymal transcriptional class and negatively correlated with EGFR
amplification, PTEN deletion and the classical transcriptional class
We used CD3G expression data to validate findings uncovered by our morphologic analysis.
There was a positive correlation (0.30) between the histologic categorization of lymphocytes
and CD3G expression (p<0.001). GBMs with higher levels of TILs had significantly higher
CD3G expression (p<0.001). Those with absent (0), present (1+) and abundant (2+)
lymphocytes had CD3G expression of 15.34 (Standard deviation (SD) ± 7.81), 17.55 (SD ±
10.99) and 20.23 (SD ± 13.51), respectively
We examined levels of CD3G expression in cases harboring mutations in RB1, TP53 and
NF1. Cases with RB1 mutations tended to have higher levels of CD3G expression than wild
type cases (19.1 vs 16.2). Cases with TP53 mutations also showed higher levels of CD3G
expression than wild type (17.4 vs 16.0). Cases with NF1 mutations had lower levels of
CD3G expression compared to wild type (15.6 vs 16.5) (all p>0.05).
We also investigated CD3G expression in EGFR-amplified and PTEN-deleted cases. EGFR-
amplified cases had lower levels of CD3G expression than wild type (15.6 vs 16.7).
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Likewise, PTEN-deleted cases also had lower levels of CD3G expression (15.5 vs 16.3)
(both p>0.05).
Finally, we analyzed CD3G expression levels by transcriptional class. There was a
statistically significant difference in expression according to transcriptional class (p<0.001).
Cases belonging to the mesenchymal transcriptional class had the highest CD3G expression
(19.6), which was significantly higher than that of other classes combined (15.1) (p<0.001).
Conversely, CD3G expression was significantly lower in the classical transcriptional class
compared to all other classes (14.8 vs 17.1) (p<0.001).
TILs are not associated with prolonged with survival
TILs were not associated with prolonged survival in univariate analyses. We compared the
survival of cases with absent (0) lymphocytes, present (1+) and abundant (2+) lymphocytes
using a log-rank test (p>0.05) (Figure 3). We found patient age was a highly significant
predictor of survival (p<0.001); however, lymphocytes did not vary according to age. The
mean age of patients with absent (0), present (1+) and abundant (2+) lymphocytes was 56.9
(SD ± 14.6), 57.3 (SD ± 12.1) and 54.8 years (SD ± 13.1), respectively (p>0.05). TILs were
not a significant predictor of survival in an age-adjusted Cox proportional hazards model
(data not shown) (p>0.05). If tumors belonging to the classical transcriptional class were
excluded, there were no survival differences according to TILs among proneural, neural and
mesenchymal tumors (p>0.05). Similarly, if mesenchymal tumors were excluded, there were
no survival differences according to TILs among proneural, neural and classical tumors
(p>0.05).
DISCUSSION
Lymphocytes are present in the stroma of many human cancers. The histologic finding of
tumor-infiltrating lymphocytes (TILs) is often associated with prolonged survival. Tumors
with TILs may have distinctive clinicopathologic features or underlying genetic alterations,
which could be relevant for future tailored therapies.
Although prognostically significant in other cancers, the clinical relevance and genetic
associations of TILs in GBM remains unclear. The TCGA data set offers an opportunity to
study the relationship between morphologic features, molecular alterations and survival in
GBM.(3, 4) Verhaak et al. used TGCA gene expression profiles to identify four
transcriptional classes, while independent studies of genome methylation uncovered a
hypermethylated, G-CIMP+ subset characterized by IDH mutations and overproduction of
the oncometabolite 2-hydroxyglutarate (2-HG).(3, 26, 29) Recent evidence suggests GBMs
within the mesenchymal transcriptional class have a better response to immunotherapy,
suggesting this class may be more immunogenic.(30) We hypothesized TILs are
differentially distributed within specific morphologic and molecular classes of GBM.
We found TILs were not uniformly distributed among GBMs, suggesting some are more
capable of eliciting an immune response. Indeed, lymphocytes were absent in over half, as
determined morphologically by a panel of TCGA neuropathologists. TILs were strongly
enriched in the mesenchymal transcriptional class of GBM, which suggests tumors
belonging to this subtype are more immunogenic. Seventy-one percent of tumors with
abundant (2+) lymphocytes belonged to the mesenchymal class. No other transcriptional
class had more than 12% with abundant (2+) TILs, indicating a fundamental difference in
transcriptional class with regard to TILs.
Variation of TILs could potentially be accounted for by the extent of necrosis, since the
mesenchymal class signature is heavily influenced by the degree of necrosis and the
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presence of lymphocytes was associated with necrosis in this study.(31) However,
mesenchymal GBMs with abundant (2+) TILs did not have substantially different levels of
necrosis than those with no TILs. Neither zonal or pseudopalisading necrosis were
associated with transcriptional class. Moreover, molecular alterations associated with the
mesenchymal class are more likely to be responsible for the association with TILs.
Lymphocytes were strongly associated with mutations in NF1 and RB1 and a trend was
noted for TP53 mutations. Mutations of NF1 and RB1 are characteristic of the mesenchymal
transcriptional class and TP53 mutations are common in both the mesenchymal and
proneural subtypes. Interestingly, we found TP53 mutant tumors with abundant (2+) TILs
were more common in the mesenchymal than the proneural class, but this did not reach
statistical significance.
We also found TILs were more common in certain morphologic subsets of GBM, including
those with sarcomatous, giant cell, epithelioid and gemistocytic components. This was of
interest since prior studies have shown gliosarcoma, giant cell glioblastoma and
gemistocytic astrocytomas are all characterized by a high frequency of TP53 mutations.(32–
34) Our own studies using TCGA data indicated sarcomatous components in GBM were
associated with NF1, RB1 and TP53 mutations; giant cells were associated with TP53 and
RB1 mutations; and epithelioid cells were associated with NF1 and RB1 mutations (data not
shown). We did not find an association between TP53 mutations and gemistocytic cells,
likely because of inclusion of tumors with low levels of this histologic finding as compared
to prior studies, which included morphologically pure gemistocytic astrocytomas of lower
grade. Nonetheless, we found the presence of TILs was strongly associated with the
mesenchymal transcriptional class as well as the mutations and tumor morphologies
associated with this gene signature.
We also found TILs were rare in tumors of the classical transcriptional class, suggesting
these may exclude lymphocytes and prevent immune-mediated tumor eradication. Only one
case with abundant (2+) lymphocytes belonged to the classical transcriptional class (1/17).
We also noted TILs were depleted in EGFR-amplified GBMs, which are frequent in the
classical transcriptional class of GBMs, but less common in other classes, including
mesenchymal. Since small cell GBMs have been shown to have a high frequency EGFR
amplification, we were also encouraged that the histologic presence of small cells within
GBMs from the TCGA data set was associated with TIL depletion.(35) Recent evidence
suggests EGFR activation may repress the adaptive immune response, potentially through
attenuation of MHCI and MHCII expression, and therefore explain the relation between
EGFR amplification and lymphocyte depletion.(36) We also found TILs were depleted in
PTEN-deleted tumors (homozygous). Loss of PTEN has been shown to increase expression
of the immunosuppressive protein B7 homolog 1 (B7-H1), and therefore may account for
the association between homozygous PTEN deletion and lymphocyte depletion.(22)
We used CD3G expression data from TCGA to validate our morphologic findings. The
CD3G gene encodes a protein that forms the T cell receptor-CD3 complex and is highly
specific to T lymphocytes and present in all subsets. The correlation between lymphocytes
and CD3G expression was highly statistically significant (p<0.001), however the strength of
the correlation was moderate (0.3). Although the tissue used for molecular analysis by
TCGA was from the same neoplasm as the tissue used to create slide images, the
distribution of TILs in tumors can be irregular and may contribute to a weak correlation. In
addition, the detection and evaluation of TILs by molecular and pathologic methods differ
considerably and may also lead to a weakened correlation. However, we were encouraged
that mutations associated with TILs (RB1 and TP53) tended to have higher levels of CD3G
expression, whereas copy number alterations associated with depletion of lymphocytes
(EGFR amplification and homozygous PTEN deletion) had lower CD3G expression.
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Tumors of the mesenchymal transcriptional class had significantly higher CD3G expression
than all other subtypes, while those of the classical subtype had significantly lower
expression, which corroborates the associations uncovered in our morphologic analysis.
GBMs annotated as having zonal necrosis by TCGA neuropathologists did not have
significantly higher levels of CD3G expression and those with pseudopalisading necrosis
had lower levels of CD3G expression, suggesting TILs may indeed represent an anti-tumor
adaptive immune response rather than a response to necrosis.
In summary, our analysis of digitized, whole slide H&E-stained images from TCGA had the
advantage of a large number of cases and high quality, multi-platform molecular analysis. It
illustrates the power of networks such as the TCGA to link multi-platform molecular
analysis to histopathologic findings in cancer with implications for future therapy. The
categorical classification of lymphocytes as 0, 1+ and 2+ was not optimal since statistical
associations with molecular and clinical variables were not as strong. We have not adjusted
for multiple comparisons since the purpose of the analysis was to identify common
molecular alterations in GBM related to the immune response for future tissue-based
analyses. However, our analysis was limited to alterations known as significant and
recurrent events in GBM pathogenesis. Furthermore, we are encouraged that each
statistically significant association has a biologic rationale. Finally, this classification does
not account for the functional activity of lymphocytes or specific lymphocyte subsets. While
effector lymphocytes are thought to mediate the anti-tumor response, regulatory
lymphocytes may suppress the cytotoxic activity of effector lymphocytes. Thus, effector and
regulatory lymphocytes may have distinct molecular and histologic associations. Future
studies that examine the molecular correlates of lymphocyte subsets will add substantially to
the field of immunotherapy.
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Statement of Translational Relevance
Tumor-infiltrating lymphocytes (TILs) are present in a subset of GBMs, suggesting some
are more capable of eliciting an adaptive immune response. We hypothesized TILs are
differentially distributed among specific molecular classes of GBM and used histologic
data linked to multiplatform molecular analysis from The Cancer Genome Atlas (TCGA)
to identify correlates. We have shown that TILs are associated with specific genomic
alterations and related to transcriptional class, which may provide insight into the
biologic significance of TILs in GBM and predict response to immunotherapy.
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Representative examples of permanent section histologic slides from TCGA cases.
Lymphocytes were identified as small round cells with scant cytoplasm and darkly staining
nuclei. Cases with a complete absence of lymphocytes were labeled 0 (absent) (top). Cases
with lymphocytes present in <50% of tumor tissue were categorized 1+ (present)
(middle).Cases with lymphocytes present in ≥50% were categorized 2+ (abundant) (bottom).
Rutledge et al. Page 13














Representative examples of GBM morphologic subtypes associated with the presence of
lymphocytes in TCGA permanent section histologic slides. TILs are enriched in GBMs with
sarcomatous cells (top), gemistocytes (middle) and giant cells (bottom).
Rutledge et al. Page 14














Kaplan–Meier estimates of survival according to absent (0), present (1+) or abundant (2+)
lymphocytes. TILs are not associated with improved survival (log-rank p>0.05).
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Table 1
18 histopathologic features were categorized as absent (0), present (1+), or abundant (2+) in 171 TCGA
GBMs. TILs are associated with specific histopathologic features in GBM.




Pseudopalisading necrosis 0.01 −0.19
Zonal necrosis 0.04 0.16
Neutrophils 0.09 0.13
Macrophages <0.001 0.32
Microvascular hyperplasia 0.59 −0.04
Endothelial hyperplasia 0.05 −0.15
Epithelial metaplasia 0.04 0.16
Gemistocytes 0.01 0.22
Giant cells 0.02 0.18
Oligodendroglial cells 0.01 −0.19
Sarcomatous metaplasia <0.01 0.22
Small cells <0.01 −0.24
Mineralization 0.68 0.03
Satellitosis 0.20 −0.10
White matter invasion 0.09 −0.13
Cortex invasion 0.71 −0.03
Mantel-Haenzel chi-square test and Spearman correlation were used to examine associations between lymphocytes (0, 1+, 2+) and other
histopathologic features (0, 1+, 2+)
Mantel-Haenzel exact chi-square test was used when 25% of the cells had <5 observations
Effective Sample Size 171
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Table 2






(0 vs 1+, 2+ combined)
Chi square p-value
(0, 1+ combined vs 2+)
TP53 33 0.13 0.06 0.15
PTEN 29 0.15 0.06 0.44
EGFR 26 0.82 0.54 1.00
NF1 16 0.03 0.74 0.04
RB1 10 0.04 0.04 0.22
PIK3R1 9 0.67 0.49 1.00
PIK3CA 7 0.72 1.00 0.50
IDH1 4 0.53 1.00 0.32
ERBB2 0 - - -
Chi-square test was used to examine associations between lymphocytes (0, 1+, 2+) and mutations (0, 1)
Fisher’s exact test was used when 25% of the cells had <5 observations
Effective Sample Size 99
Categories were combined to identify associations driven by cases with either complete absence or abundance of lymphocytes
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Table 3






(0 vs 1+, 2+ combined)
Chi square p-value
(0, 1+ combined vs 2+)
Amplifications
EGFR 49.3 0.05 0.04 0.06
CDK4 14.5 0.37 0.22 0.47
PDGFRA 14.1 0.61 0.73 0.47
MDM4 9.9 0.23 0.24 0.64
MDM2 9.3 0.81 0.82 1.00
MET 8.8 0.57 0.79 0.48
CDK6 7.0 0.75 0.65 0.69
CCND2 4.0 1.00 1.00 1.00
AKT3 3.2 1.00 1.00 1.00
MYCN 2.6 1.00 0.62 1.00
PIK3CA 2.4 0.69 0.60 1.00
Deletions
CDKN2A 62.0 0.23 0.09 0.48
CDKN2B 61.0 0.23 0.09 0.48
PTEN 10.3 0.09 0.03 0.69
RB1 3.6 0.87 1.00 0.57
CDKN2C 3.6 0.71 1.00 0.51
PARK2 2.0 1.00 1.00 1.00
NF1 1.2 0.07 0.10 0.30
Chi-square test was used to examine associations between lymphocytes (0, 1+, 2+) and CNAs
Fisher’s exact test was used when 25% of the cells had <5 observations
Effective Sample Size 153
Categories were combined to identify associations driven by cases with either complete absence or abundance of lymphocytes
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